76-Year-Old Patient, Not on Antithrombotic Therapy, Presenting to ED After Ground-Level Fall (Glasgow Coma Scale of 15)

March 25, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), antithrombotic therapy was not linked to increased incidence of traumatic intracranial hemorrhage on CT in adult patients, although the therapy did show association with hematoma expansion at follow-up.

“The findings suggest, in patients with good neurological status after ground-level fall, application of a similar strategy for selecting patients for initial head CT, regardless of antithrombotic therapy use,” wrote first author Zeynep Vardar, M.D., at the University of Massachusetts Medical Center in Worcester. “If initial head CT shows traumatic intracranial hemorrhage, early follow-up head CT should be systematically performed in those on antithrombotic therapy though possibly deferred in other patients.”

Vardar and colleagues’ retrospective case-control study included 1,630 patients (693 female, 937 male; mean age, 80 years) who underwent head CT after presenting to the emergency department (ED) with ground-level fall (Glasgow Coma Scale ≥ 14 and no focal neurological deficit) between January 1 and December 31, 2020. Initial head CT examinations were reviewed for traumatic intracranial hemorrhage characteristics and follow-up head CT examinations (performed within 24 hours) were reviewed for hematoma expansion, with clinical outcomes extracted from medical records.

The frequency of intracranial hemorrhage after ground-level fall with good neurological status was not significantly different between patients on antithrombotic therapy and those not on antithrombotic therapy (4.4% vs 3.1% respectively, p = .24). However, hematoma expansion occurred more frequently in patients on antithrombotic therapy (26.2% vs 4.8%, p = .04).

Also noting no significant difference between patients on anticoagulant therapy alone, antiplatelet therapy alone, or both, “the frequency of midline shift and regional mass effect was not significantly different between patients on antithrombotic therapy and control patients,” the authors of this AJR article added.

For more information: www.arrs.org

Related Content

News | Radiology Business

July 1, 2022 — Richard Fabian has been promoted to the role of Chief Executive Officer (CEO) of Fujifilm Sonosite, Inc ...

Time July 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

June 30, 2022 — When a patient with head and neck cancer has surgery to remove it, they often need reconstructive ...

Time June 30, 2022
arrow
News | Radiology Business

June 29, 2022 — Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed ...

Time June 29, 2022
arrow
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Time June 24, 2022
arrow
News | Lung Imaging

June 24, 2022 — Xoran Technologies announced they have begun work on Phase 2 of their mobile lung grant with the goal to ...

Time June 24, 2022
arrow
News | Digital Radiography (DR)

June 22, 2022 — Canadian manufacturer KA Imaging unveiled a new brand identity for its patented dual-energy technology ...

Time June 22, 2022
arrow
News | Computed Tomography (CT)

June 16, 2022 — Xoran Technologies has recently received a patent for a modular computed tomography (CT) system assembly ...

Time June 16, 2022
arrow
News | Artificial Intelligence

June 14, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), incorporating AI support into clinical ...

Time June 14, 2022
arrow
News | PET-CT

June 14, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and ...

Time June 14, 2022
arrow
News | SPECT-CT

June 13, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Symbia Pro ...

Time June 13, 2022
arrow
Subscribe Now